Arcutis Q1 Product Revenue Soars 65% Year-Over-Year, Net Loss Significantly Narrows
ARQT sits 83% above its 52-week low of $12.42.
Summary
Arcutis Biotherapeutics reported strong first-quarter results, with product revenue surging 65% year-over-year to $105.4 million. The company also significantly narrowed its net loss to $11.3 million, or $0.09 per share. This positive performance was driven by robust unit demand and improvements in gross-to-net sales deductions, despite a sequential decline attributed to typical Q1 seasonality. Management reiterated its full-year 2026 net product revenue guidance of $480 million to $495 million, signaling confidence in continued growth. Traders will be watching for sustained ZORYVE adoption and the impact of the recently expanded dermatology sales force on future quarters.
At the time of this announcement, ARQT was trading at $22.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $12.42 to $31.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.